Provided by Tiger Fintech (Singapore) Pte. Ltd.

23andMe, Inc.

1.92
+0.10505.79%
Post-market: 1.940.0200+1.04%19:59 EDT
Volume:145.62K
Turnover:277.26K
Market Cap:51.51M
PE:-0.12
High:2.00
Open:1.80
Low:1.80
Close:1.82
Loading ...

Company Profile

Company Name:
23andMe, Inc.
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
571
Office Location:
349 Oyster Point Boulevard,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications; and Lemonaid telehealth platform, patients can access affiliated licensed healthcare professionals for medical consultation and treatment for several common conditions, as well as research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline plc to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

Directors

Name
Position
Anne Wojcicki
Chief Executive Officer and President and Chairman
Neal Mohan
Independent Director
Patrick Chung
Independent Director
Peter J. Taylor
Independent Director
Roelof Botha
Independent Director
Sandra Hernandez
Independent Director
Valerie Montgomery Rice
Independent Director
Richard Scheller
Director

Shareholders

Name
Position
Anne Wojcicki
Chief Executive Officer and President and Chairman
Joseph Selsavage
Interim Chief Financial and Accounting Officer
Kathy Hibbs
Chief Administrative Officer
Kenneth Hillan
Chief Therapeutics Officer
Paul Johnson
Vice President, Europe